G. Thomas Budd on Genomic Profiling for Targeted Therapies

Video

G. Thomas Budd, MD, medical oncologist, Taussig Cancer Center at Cleveland Clinic, discusses genomic profiling for targeted therapies.

G. Thomas Budd, MD, medical oncologist, Taussig Cancer Center at Cleveland Clinic, discusses genomic profiling for targeted therapies.

Genomic profiling is not commonly done because of the expense, Budd says, but there is pressure to make the technology more widely available available to patients.

Budd adds that genomic profiling is still being studied in clinical trials. The NCI-MATCH trial, for example, patients will undergo genomic profiling to determine whether they have a genetic mutation or molecular abnormality that will respond to a targeted drug.

Recent Videos
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
5 experts in this video
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content